## SHORT COMMUNICATIONS

**Role of Intestinal Cytochrome P450 (P450) in Modulating the Bioavailability of Oral Lovastatin: Insights from Studies on the Intestinal Epithelium-Specific P450 Reductase Knockout Mouse.** Yi Zhu, Jaime D’Agostino, and Qing-Yu Zhang

Cytochrome P450 2S1 is Reduced by NADPH-Cytochrome P450 Reductase.

Yi Xiao, Raku Shinkyo, and F. Peter Guengerich

The Tissue-Specific Toxicity of Methimazole in the Mouse Olfactory Mucosa Is Partly Mediated through Target-Tissue Metabolic Activation by CYP2A5.

Fang Xie, Xin Zhou, Mary Beth Genter, Melissa Behr, Jun Gu, and Xinxin Ding

## ARTICLES

Absorption, Distribution, Metabolism, and Excretion of [14C]GDC-0449 (Vismodegib), an Orally Active Hedgehog Pathway Inhibitor, in Rats and Dogs: A Unique Metabolic Pathway via Pyridine Ring Opening.

Qin Yue, Yung-Hsiang Chen, Teresa Mulder, Alan Deese, Ryan Takahashi, Patrick J. Rudewicz, Mark Reynolds, Eric Solon, Cornelis E. C. A. Hop, Harvey Wong, and S. Cyrus Khosravshesh

Suppression of Cytochrome P450 Reductase (POR) Expression in Hepatoma Cells Replicates the Hepatic Lipidosis Observed in Hepatic POR-Null Mice.

Todd D. Porter, Subhashis Banerjee, Elzbieta I. Stolarczyk, and Ling Zou

Substituted Imidazole of 5-Fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates Cytochrome P450 2D6 by Protein Adduction.


Quantitative Time-Lapse Imaging-Based Analysis of Drug-Drug Interaction Mediated by Hepatobiliary Transporter, Multidrug Resistance-Associated Protein 2, in Sandwich-Cultured Rat Hepatocytes.

Takeo Nakanishi, Yuta Shibue, Yoko Fukuyama, Kenji Yoshida, Hajime Fukuda, Yoshitoki Shirasaka, and Ikumi Tamai

Alteration of Hepatic but Not Renal Transporter Expression in Diet-Induced Obese Mice.

Vijay R. More and Angela L. Sitt

ATP-Binding Cassette Transporter Expression in Human Placenta as a Function of Pregnancy Condition.

Cifford W. Mason, Irina A. Buhimschi, Catalin S. Buhimschi, Yafeng Dong, Carl P. Weiner, and Peter W. Swaan

Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs That Exhibit Both Active Secretion and Net Reabsorption.

Stuart W. Paine, Karellle Menochet, Rebecca Denton, Dermot F. McGinnity, and Robert J. Riley

Studies on the Metabolism and Biological Activity of the Epimers of Sulindac.

David Brunell, Daphna Sager, Shailaja Kesaraat, Nathan Brot, and Herbert Weissbach

Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by Lapatinib.

Hideo Takakusa, Michelle D. Wahlin, Chunsheng Zhao, Kelsey L. Hanson, Lee Sun New, Eric Chin Yong Chan, and Sidney D. Nelson

Continued on next page
Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments. Takao Watanabe, Hirohito Kusuhara, Tomoko Watanabe, Yasuyuki Debori, Kazuya Maeda, Tsunenori Kondo, Hideki Nakayama, Shigeru Horita, Brian W. Ogilvie, Andrew Parkinson, Zhuohan Hu, and Yuichi Sugiyama

CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs. Alfred Zimmerman, Markus Trunzer, and Bernard Faller

Influence of Non-Steroidal Anti-Inflammatory Drugs on Organic Anion Transporting Polypeptide (OATP) 1B1- and OATP1B3-Mediated Drug Transport. Juergen Kindla, Fabian Müller, Maren Mieth, Martin F. Fromm, and Jörg König

A Refined Cytochrome P450 IC50 Shift Assay for Reliably Identifying CYP3A Time-Dependent Inhibitors. Ping Li, Chuang Lu, Suresh K. Balani, and Liang-Shang Gan


Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir. Brian J. Kirby, Ann C. Collier, Evan D. Kharasch, Dale Whittington, Kenneth E. Thummel, and Jashvant D. Unadkat


Pharmacokinetics and Hepatic Uptake of Eltrombopag, a Novel Platelet-Increasing Agent. Kazuya Takeuchi, Tomoko Sugiura, Saki Umeda, Kazuki Matsubara, Masato Horikawa, Noritaka Nakamichi, David L. Silver, Norihisa Ishiwata, and Yukio Kato


Pharmacokinetics of the Monohydroxy Derivative of Oxcarbazepine and Its Enantiomers after a Single Intravenous Dose Given as Racemate Compared with a Single Oral Dose of Oxcarbazepine. G. Flesch, C. Czendlik, D. Renard, and P. Lloyd

ERRATUM

Correction to “Disposition and Metabolism of [14C]SB-649868, an Orexin 1 and 2 Receptor Antagonist, in Humans”.

Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: A whole-body autoradiogram of the radioactivity distribution in female Long-Evans rats. See the article by Yue et al. on page 952 of this issue.